Naiyer Rizvi named director of thoracic oncology at NewYork-Presbyterian/Columbia University Medical Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NAIYER RIZVI was named director of thoracic oncology and immunotherapeutics in medical oncology at NewYork-Presbyterian/Columbia University Medical Center.

Rizvi comes from Memorial Sloan Kettering Cancer Center, where he was an attending physician and focused on thoracic immunotherapy.

He has authored or co-authored more than 60 peer-reviewed papers, books and book chapters, and currently sits on the editorial board of OncoImmunology.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login